The Latest Updates from CNSide Diagnostics
CNSide Team Supports Cancer Research at the Winship 5K During Breast Cancer Awareness Month
This past weekend, CNSide Diagnostics’ Andrew Sims and Conroy Campbell proudly participated in the Winship 5K in support of the Winship Cancer Institute of Emory University and its mission to advance lifesaving cancer research. Held during Breast Cancer Awareness...
UnitedHealthcare National Coverage Agreement for CNSide® on FINTECH.TV
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently traveled to the New York Stock Exchange (NYSE) to join Remy Blaire of FINTECH.TV for an in-depth discussion on the company’s National Coverage Agreement with UnitedHealthcare Insurance...
Plus Therapeutics CEO Discusses UnitedHealthcare National Coverage Agreement for CNSide® CSF Assay
Marc Hedrick, M.D., President and CEO of Plus Therapeutics (Nasdaq: PSTV), recently sat down with Jonathan D. Grinstein, PhD, of Inside Precision Medicine to discuss the company’s exciting news: a National Coverage Agreement with UnitedHealthcare Insurance Company...
CNSide Diagnostics Welcomes Kelly Kreitzburg Ondrasek, PhD, as Medical Science Liaison
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is pleased to announce the addition of Kelly Kreitzburg Ondrasek, PhD, as Medical Science Liaison (MSL). Dr. Kreitzburg Ondrasek brings extensive scientific expertise and a...
CNSide Diagnostics President & GM Russell Bradley Featured in InnovationMap Interview on Advancing CNS Cancer Detection
Russell Bradley, President and General Manager of CNSide Diagnostics, was recently featured in an interview with InnovationMap, where he discussed the company’s CNSide® Cerebrospinal Fluid (CSF) Assay Platform — an advanced diagnostic designed to help clinicians...
National Agreement With UnitedHealthcare to Expand Access to CNSide® CSF Tumor Cell Enumeration Test
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced today that it has entered into a national agreement with UnitedHealthcare Insurance Company (NYSE: UNH) to provide access to its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory-developed test (LDT)....
CNSide Diagnostics Welcomes Elaine Luckey as Director of Quality
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is excited to announce the addition of Elaine Luckey as the company’s new Director of Quality. Elaine brings extensive experience in quality management systems, regulatory...
CNSide Receives CMS Certificate of Accreditation for Houston Laboratory
Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that its state-of-the-art clinical laboratory in Houston, Texas, has successfully earned a Certificate of Accreditation from the Centers for Medicare & Medicaid Services (CMS). The accreditation follows a...
CNSide Diagnostics Welcomes Tramel Pennie as Senior Laboratory Technician
CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is proud to announce the addition of Tramel Pennie to its growing team as Senior Laboratory Technician. Tramel brings valuable experience in clinical laboratory operations...
CNSide Expert Panel Recording: Advancing LM Diagnostics and Care
Expert Insights on LM Care CNSide Diagnostics is proud to share the recording of last month’s expert panel on leptomeningeal metastases (#LM) from the Society for Neuro-Oncology (SNO)/American Society of Clinical Oncology (ASCO) CNS Metastases Conference. Leading...